Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05719441 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
A Phase 2 study of Acute HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT05719441 is a Phase 2 study of Acute HIV Infection that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT05719441, a Phase 2 study of Acute HIV Infection, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks compared to participants who receive placebo plus ART. * Participants who receive combination bNAb therapy in addition to ART during AHI will demonstrate lower viral reservoirs and enhanced HIV-specific immunity compared to participants who receive placebo plus ART.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VRC07-523LS
- BIOLOGICAL PGT121.414.LS
- DRUG ART
Study Locations (20)
California
- 1201, University of Southern California CRS - Los Angeles
- 601, University of California, Los Angeles CARE Center CRS - Los Angeles
- 701, UCSD Antiviral Research Center CRS - San Diego
- 801, University of California, San Francisco HIV/AIDS CRS - San Francisco
- 603, Harbor University of California Los Angeles Center CRS - Torrance
New York
- 7804, Weill Cornell Chelsea CRS - New York
- 30329, Columbia Physicians & Surgeons (P&S) CRS - New York
- 7803, Weill Cornell Uptown CRS - New York
- 31787, University of Rochester Adult HIV Therapeutic Strategies Network CRS - Rochester
Illinois
- 2701, Northwestern University CRS - Chicago
- 2702, Rush University CRS - Chicago
Massachusetts
- 101, Massachusetts General Hospital CRS (MGH CRS) - Boston
- 107, Brigham and Women's Hospital Therapeutics (BWH TCRS) CRS - Boston
Alabama
- 31788, Alabama CRS - Birmingham
Colorado
- 6101, University of Colorado Hospital CRS - Aurora
District of Columbia
- 31791, Whitman-Walker Institute, Inc. CRS - Washington D.C.
Georgia
- 5802, The Ponce de Leon Center CRS - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2028-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05719441
The ClinicalTrials.gov registry entry for NCT05719441 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute HIV Infection appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05719441 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT05719441 about?
NCT05719441 is a clinical study titled "A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission". A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in a...
What is the current status of trial NCT05719441?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-08-19. Estimated completion is 2028-09-06.
What conditions does trial NCT05719441 study?
This clinical trial studies the following conditions: Acute HIV Infection.
What interventions are being tested in trial NCT05719441?
The interventions under investigation include: Placebo (OTHER), VRC07-523LS (BIOLOGICAL), PGT121.414.LS (BIOLOGICAL), ART (DRUG).
Who is sponsoring clinical trial NCT05719441?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05719441 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.